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Background: Conventional tests are not always helpful in making a diagnosis of
tuberculous pleurisy. Many studies have investigated the usefulness of adenosine
deaminase (ADA) in pleural fluid for the early diagnosis of tuberculous pleurisy. We
conducted a meta-analysis to determine the accuracy of ADA measurements in the
diagnosis of tuberculous pleurisy.
Methods: After a systematic review of English language studies, sensitivity, specificity,
and other measures of accuracy of ADA concentration in the diagnosis of pleural effusion
were pooled using random effects models. Summary receiver operating characteristic
curves were used to summarize overall test performance.
Results: Sixty-three studies met our inclusion criteria. The summary estimates for ADA in
the diagnosis of tuberculous pleurisy in the studies included were sensitivity 0.92 (95%
confidence interval 0.90–0.93), specificity 0.90 (95% confidence interval 0.89–0.91),
positive likelihood ratio 9.03 (95% confidence interval 7.19–11.35), negative likelihood
ratio 0.10 (95% confidence interval 0.07–0.14), and diagnostic odds ratio 110.08 (95%
confidence interval 69.96–173.20).
Conclusions: ADA determination is a relative sensitive and specific test for the diagnosis of
tuberculous pleurisy. Measurement of ADA in pleural effusion is thus likely to be a useful
diagnostic tool for tuberculous pleurisy. The results of ADA assays should be interpreted in
parallel with clinical findings and the results of conventional tests.
& 2008 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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In China, the prevalence of active pulmonary tuberculosis in
2000 was 367 per 100,000, the prevalence of smear positive
pulmonary tuberculosis was 122 per 100,000, and the
prevalence of bacteriological positive pulmonary tubercu-
losis was 160 per 100,000.1 There were an estimated 8.9
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ADA in diagnosis of TB pleurisy 745million new cases of tuberculosis in 2004, fewer than half of
which were reported to public-health authorities and World
Health Organization.2 Tuberculous pleural effusion (TPE) is
caused by a severe delayed-type hypersensitivity reaction in
response to the rupture of a subpleural focus of Mycobac-
terium tuberculosis (MTB) infection. The inflammatory
process results in an increased pleural vascular permeability
leading to the accumulation of fluid enriched in proteins and
the recruitment of specific leukocytes into the pleural
space.3 Many studies have investigated the usefulness of
adenosine deaminase (ADA) in pleural fluid for the early
diagnosis of TPE, and two early meta-analyses have shown
that diagnostic value of pleural ADA measurement for TPE
was reasonably good4,5; however, likelihood ratios including
both positive likelihood ratio (PLR) and negative likelihood
ratio (NLR), and diagnostic odds ratio (DOR) have not been
evaluated in those meta-analyses. In those two meta-
analyses, only parts of reports published in the year 2000
and before were included. Since that time, additional
clinical studies determining the concentrations of ADA have
been reported. Although the accuracy of ADA detection for
the diagnosis of TPE has been extensively studied, the exact
role of these detections remains controversial. We per-
formed the present meta-analysis to establish the overall
accuracy of ADA measurement for the diagnosis of TPE.
Methods
Search strategy and study selection
We searched Embase, Ovid, Web of Science, Cochrane
database, and Medline (using PubMed as the search engine)
to identify suitable studies until March 2007; no lower date
limit was applied. Articles were also identified by the use of
the related-articles function in PubMed. References of
articles identified were also searched manually. The search
terms were ‘‘tuberculosis’’, ‘‘MTB’’, ‘‘pleurisy/pleuritis’’,
‘‘pleural effusion/pleural fluid’’, ‘‘adenosine deaminase/Table 1 Summary of included studies.
Citing no. Study Numbers of
patients
Method
16 Piras16 54 Giusti
17 Blake17 202 Non-Giusti
18 Maritz18 368 Giusti
19 Pettersson19 91 Giusti
20 Niwa20 58 Unknown
21 Raj21 55 Giusti
22 Sinha22 53 Giusti
23 Strankinga23 86 Giusti
24 Teo24 92 Giusti
25 Fontan Bueso25 138 Giusti
26 Kim26 50 Giusti
27 Ocana27 586 Giusti
28 Gilhotra28 73 Giusti
29 Hsu29 48 Giusti
30 Moriwaki30 51 Non-Giusti
31 Segura31 600 GiustiADA’’, ‘‘sensitivity and specificity’’, and ‘‘accuracy’’. We
contacted experts in the specialty, and searched the
reference lists from primary and review articles. Although
no language restrictions were imposed initially, for the full-
text review and final analysis our resources only permitted
review of English articles. Conference abstracts and letters
to the journal editors were excluded because of the limited
data presented in them.
A study was included in the meta-analysis when it
provided both sensitivity (true positive rate) and specificity
(1-false positive rate) of ADA for the diagnosis of TPE, or
when it provided ADA values in a dot plot form, allowing test
results to be extracted for individual study subjects. The
studies including at least 10 TPE specimens were selected in
the study, since very small studies may be vulnerable to
selection bias. Two reviewers (QLL and HZS) independently
judged study eligibility while screening the citations.
Disagreements were resolved by consensus.Data extraction and quality assessment
The final set of English articles was assessed independently
by two reviewers (QLL and HZS). The reviewers were blinded
to publication details such as the author, the country in
which the study was performed, the name of journal and
publication year, etc., and disagreements were resolved by
consensus. Data retrieved from the reports included author,
publication year, participant characteristics, test methods,
cut-off value, sensitivity and specificity data, and metho-
dological quality. Where pleural ADA values were provided in
dot plots, scalar grids were placed over the plots and the
values were measured and used to produce a receiver
operating characteristic (ROC) curve for each study (SPSS
version 14.0 Statistical Software, Chicago, IL). The numbers
of true positive, false positive, false negative, and true
negative are displayed for each study in Table 1.
We assessed the methodological quality of the studies
using guidelines published by the STARD (standards forCut-off
(IU/L)
TP FP FN TN Quality score
STARD QUADAS
30 21 0 0 33 5 4
30 74 2 8 118 9 9
40 100 49 7 212 9 9
30 19 10 0 62 8 9
30 22 4 6 26 9 9
40 30 1 0 24 9 9
30 37 0 0 16 11 10
53 10 10 0 66 11 9
50 24 6 1 61 11 9
33 61 7 0 70 9 7
41 25 3 3 19 10 9
43 170 25 0 391 8 9
40 30 4 0 39 8 9
50 18 8 1 21 10 9
33 14 2 0 35 10 9
71 170 35 0 395 10 9
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Table 1 (continued )
Citing no. Study Numbers of
patients
Method Cut-off
(IU/L)
TP FP FN TN Quality score
STARD QUADAS
32 Baganha32 73 Giusti 40 35 0 0 38 8 9
33 Gupta33 53 Giusti 50.8 36 1 0 16 9 9
34 Banales34 218 Giusti 70 81 6 1 130 12 10
35 Maartens35 109 Giusti 45 47 8 14 40 11 9
36 Shimokata36 29 Non-Giusti 30 12 1 1 15 6 5
37 Kaur37 73 Giusti 30 14 4 7 48 11 7
38 Muranishi38 67 Giusti 50 16 8 18 25 11 9
39 Nagaraja39 30 Giusti 50 15 0 0 15 12 9
40 Prasad40 47 Unknown 30 21 0 0 26 10 9
41 Valdes41 405 Giusti 47 91 16 0 298 8 5
42 Aoki42 39 Non-Giusti 45 9 3 2 25 12 10
43 Chiang43 93 Giusti 45 23 3 4 63 10 9
44 DeOliveira44 276 Giusti 40 51 31 3 191 12 11
45 Burgess45 443 Giusti 50 139 32 15 257 13 10
46 Querol46 107 Non-Giusti 45 18 2 3 84 12 10
47 Orphanidou47 97 Giusti 40 31 6 2 58 10 9
48 Shibagaki48 66 Non-Giusti 30 31 0 2 33 9 9
49 Valdes49 350 Giusti 47 76 25 0 249 13 10
50 Villena50 228 Non-Giusti 33 44 9 5 170 14 12
51 Kim51 47 Non-Giusti 32 18 2 9 18 12 9
52 Ogawa52 41 Unknown 33 15 5 1 20 9 5
53 Ghelani53 81 Giusti 40 41 16 13 11 11 9
54 Perez-Rodriguez54 103 Non-Giusti 40 24 6 3 70 11 9
55 Riantawan55 216 Giusti 60 95 19 5 97 14 12
56 Villegas56 131 Giusti 45.5 53 10 8 60 12 9
57 Gorguner57 87 Giusti 50 33 6 3 45 11 9
58 Lim58 28 Non-Giusti 40 10 2 1 15 10 9
59 Nagesh59 60 Giusti 50 11 27 9 33 16 13
60 Reechaipichitkul60 132 Giusti 48 40 16 10 66 16 12
61 Sharma61 75 Giusti 35 40 9 8 18 14 12
62 Yamada62 63 Non-Giusti 45 18 5 3 37 12 10
63 Andreasyan63 69 Non-Giusti 20 45 2 2 20 10 9
64 Aoe64 46 Non-Giusti 40 10 3 0 33 11 9
65 Lima65 45 Giusti 40 11 8 5 21 10 9
66 Porcel66 392 Non-Giusti 40 92 11 14 275 13 10
67 Tahhan67 54 Giusti 40 20 4 2 28 8 5
68 Chen68 210 Non-Giusti 55.8 55 12 8 135 13 10
69 Neves69 215 Giusti 39 99 19 5 92 8 9
70 Poyraz70 45 Giusti 45 13 0 2 30 13 8
71 El-Ansary71 39 Giusti 35 12 2 3 22 10 9
72 Gaga72 70 Giusti 50 35 1 1 33 12 10
73 Moon73 111 Giusti 45 46 3 11 51 13 9
74 Okamato74 43 Non-Giusti 32 11 1 0 31 10 9
75 Sharma75 52 Giusti 33 32 0 3 17 12 10
76 Tozkoparan76 63 Unknown 50 31 2 3 27 11 9
77 Celik77 45 Giusti 35.6 17 0 0 28 11 9
78 Morimoto78 65 Non-Giusti 57 15 1 4 45 11 9
TP: true positive; FP: false positive; FN: false negative; TN: true negative; STARD: standards for reporting diagnostic accuracy
(maximum score 25); QUADAS: quality assessment for studies of diagnostic accuracy (maximum score 14).
Q.-L. Liang et al.746reporting diagnostic accuracy, maximum score 25) initiative6
(i.e., guidelines that aim to improve the quality of reporting
in diagnostic studies) and the QUADAS (quality assessment
for studies of diagnostic accuracy, maximum score 14) tool7(i.e., appraisal by the use of empirical evidence, expert
opinion, and formal consensus to assess the quality of
primary studies of diagnostic accuracy). In addition, the
following methodological and clinical characteristics from
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ADA in diagnosis of TB pleurisy 747each study were also retrieved: (1) diagnostic standard
(all with gold standard versus in part with gold standard);
(2) ADA assay method (Giusti method versus non-Giusti
methods); (3) cut-off value (440 IU/L versus p 40 IU/L);
and (4) with or without empyema or transudative effusion
included in non-TPE group.
Statistical analyses
We used standard methods recommended for meta-analyses
of diagnostic test evaluations.8 Analyses were performed
using STATA version 9.0 (Stata Corporation, Texas) and Meta-
DiSc (Zamora J, Muriel A, Abraira V. Meta-DiSc for Windows,
XI Cochrane Colloquium. Barcelona, 2003). We computed
the following measures of test accuracy for each study:
sensitivity, specificity, PLR, NLR, and DOR.
The analysis was based on a summary ROC (SROC)
curve.8,9 The sensitivity and specificity for the single test
threshold identified for each study were used to plot an
SROC curve.9,10 A random-effect model was used to
calculate the average sensitivity, specificity, and the other
measures across studies.11,12
Heterogeneity in meta-analyses refers to the degree of
variability in results across studies. We used the Chi-square
and Fisher’s exact tests to detect statistically significant
heterogeneity. To assess the effects of STARD and QUADAS
scores, as well as some methodological and clinical
characteristics, such as diagnostic standard, ADA assay
method, with or without empyema or transudative effusion
included in non-TPE group, on the diagnostic ability of
ADA, we included them as covariates in univariate meta-
regression analysis (inverse variance weighted). The relative
DOR (RDOR) was calculated according to standard methods
to analyze the change in diagnostic accuracy in the study per
unit increase in the covariate.13,14 Since publication bias is
of concern for meta-analyses of diagnostic studies, we
tested for the potential presence of this bias using funnel
plots and the Egger test.15
Results
After independent review, 91 publications dealing with
pleural ADA concentrations for diagnosis of TPE were
considered to be eligible for inclusion in the analysis.16–106
Of these publications, five were excluded because they
recruited less than 10 patients in a group studied,79–83 three
were excluded because they included TPE and tuberculous
peritoneal effusions as a single group,84–86 five were
excluded because the same authors published several reports
on the same patients, and only the best-quality study was
considered,87–91 15 were excluded because they did not
allow the calculation of sensitivity or specificity.92–106
Subsequently, 63 studies16–78 included 2796 patients with
TPE and 5297 non-TPE were available for analysis, and the
clinical characteristics of these studies, along with STARD
and QUADAS scores, are outlined in Table 1.
The average samples size of the studies included was 138
(range from 28 to 600). In all 63 studies included, the study
by Piras16 did not mention the diagnosis standard for TPE; in
28 studies, the diagnosis TPE was made by bacteriological or
histological studies or both (gold standard); in the remaining34 studies, some TPE patients were diagnosed based on
‘‘gold standard’’, and some patients were diagnosed based
on clinical course, including clinical presentation, pleural
fluid analysis, radiology and the responsiveness to anti-
tuberculous chemotherapy. As shown in Table 1, four studies
did not mention the assay methods for determining ADA
concentrations, Giusti method was applied in 42 studies and
non-Giusti methods were used in 17 studies. In all 63 studies
included, the cut-off value was 440 IU/L in 29 studies and
p40 IU/L in 34 studies. Empyema specimen were included in
non-TPE group in 22 studies, and not in 13 studies, in the
remaining 28 studies the authors did not indicate whether or
not they recruited the patients with empyema. Transudative
effusion specimen was included in non-TPE group in 34
studies, and not in 20 studies, in the remaining nine studies
the authors did not indicate whether or not they recruited
the patients with transudative pleural effusion.
We also noted that the cut-off values (mean7SEM) of
studies including transudates (n ¼ 34) and those that do not
(n ¼ 20) were 43.171.6 IU/L and 39.271.8 IU/L, respec-
tively, and they were not different statistically (t ¼ 1.560,
p ¼ 0.125). In addition, the cut-off value of studies using
Giusti method (n ¼ 42, 44.071.4 IU/L) was much higher
than that of those using non-Giusti method (n ¼ 17,
38.172.3 IU/L, t ¼ 2.172, p ¼ 0.034).Diagnostic accuracy
Figure 1 shows the forest plot of sensitivity and specificity
for 63 ADA assays in the diagnosis of TPE. The sensitivity
ranged from 0.47 to 1.00 (mean 0.92, 95% CI 0.90–0.93),
while specificity ranged from 0.41 to 1.00 (mean 0.90, 95%
CI 0.89–0.91). We also noted that PLR was 9.03 (95% CI
7.19–11.35), NLR was 0.10 (95% CI 0.07–0.14), and DOR was
110.08 (95% CI 69.96–173.20). X2 values of sensitivity,
specificity, PLR, NLR, and DOR were 327.03, 303.79,
380.14, 381.73, and 291.60, respectively, with all p values
o0.001, indicating a significant heterogeneity between
studies.
Unlike a traditional ROC plot that explores the effect of
varying thresholds (cut points for determining test positives)
on sensitivity and specificity in a single study, each data
point in the SROC plot represents a separate study. The SROC
curve presents a global summary of test performance, and
shows the trade off between sensitivity and specificity. A
graph of the SROC curve for the ADA determination showing
true-positive rates versus false-positive rates from indivi-
dual studies is shown in Figure 2. As a global measure of test
efficacy we used the intersection point of the SROC curve
with a diagonal line from the left upper corner to the right
lower corner of the ROC space, which corresponds to the
highest common value of sensitivity and specificity for the
test. This point does not indicate the only or even the best
combination of sensitivity and specificity for a particular
clinical setting, but represents an overall measure of the
discriminatory power of a test. Our data showed that the
SROC curve is positioned near the desirable upper left
corner of the SROC curve, and that the maximum joint
sensitivity and specificity was 0.91, while area under curve
(AUC) was 0.96 (weighted AUC was 0.95), indicating a
relative high level of overall accuracy.
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Figure 1 Forest plot of estimates of sensitivity and specificity for adenosine deaminase assays in the diagnosis of tuberculous
pleurisy. The point estimates of sensitivity and specificity from each study are shown as solid circles and the size of each study is
indicated by the size of the solid circle. Error bars are 95% confidence intervals. Numbers indicate the reference numbers of studies
cited in the reference list.
Q.-L. Liang et al.748Multiple regression analysis and publication bias
By the use of STARD guidelines,6 a quality score for every
study was compiled on the basis of title and introduction,
methods, results, and discussion (Table 1). Quality scoring
was also done by the use of QUADAS,7 in which a score of 1was given when a criterion was fulfilled, 0 if a criterion was
unclear, and 1 if the criterion was not achieved (Table 1).
These scores were used in the meta-regression analysis to
assess the effect of study quality on RDOR of ADA in the
diagnosis of TPE. As shown in Table 2, studies with higher
quality (STARDX11 or QUADASX10) produced RDOR that
ARTICLE IN PRESS
ADA in diagnosis of TB pleurisy 749were not significantly higher than those with lower quality.
We also noted that diagnostic standard (all with gold
standard versus in part with gold standard), ADA assayFigure 2 Summary receiver operating characteristic curves for
adenosine deaminase assays. Each solid circle represents each
study in the meta-analysis. The size of each study is indicated
by the size of the solid circle.
Table 2 Weighted meta-regression of the effects of study desig
of pleural adenosine deaminase.
Covariate Numbers of
studies
STARD score
X11 34
o11 29
QUADAS score
X10 16
o10 47
Diagnosis standard
Gold standard 28
Gold standard or clinical course 34
Assay method
Giusti method 42
Non-Giusti methods 17
Cut-off value
440 IU/L 29
p40 IU/L 34
Empyema
Included in non-TPE group 22
Not included in non-TPE group 13
Transudate
Included in non-TPE group 34
Not included in non-TPE group 20
RDOR: relative diagnostic odds ratio; CI: confidence interval; STARD
assessment for studies of diagnostic accuracy; TPE: tuberculous pleumethod (Giusti method versus non-Giusti methods), cut-off
value (440 IU/L versus p40 IU/L), with or without empye-
ma or transudative effusion included in non-TPE group did
not substantially affect diagnostic accuracy (Table 2).
Evaluation of publication bias showed that the Egger test
was significant (po0.001). The funnel plots for publication
bias (Figure 3) also show some asymmetry. These results
indicate a potential for publication bias.
Discussion
Making a differential diagnosis between TPE and non-TPE is
a critical clinical problem, and the conventional methods,
such as direct examination of pleural fluid by Ziehl–Neelsen
staining, culture of pleural fluid, and pleural biopsy, are
not always helpful in making the diagnosis, since they
have limitations. Microscopy of the pleural fluid is rarely
positive (o5%).103,107,108 Culture of pleural fluid has low
sensitivity (24–58%), and several weeks are required to grow
MTB.108,109 Biopsy of pleural tissue, and culture of biopsy
material are widely held to be the best methods of
confirming the diagnosis.103,107 Although not perfect, cul-
ture and/or biopsy, therefore, are widely considered the
standard of diagnosis.107 However, pleural biopsy is invasive,
operator-dependent, and technically difficult (particularly
in children).110 Sometimes, differential diagnosis of TPE
mandates more invasive procedures like thoracoscopy orn and methodological characteristics on diagnostic accuracy
Coefficient RDOR (95% CI) p-Value
1.151 0.32 (0.10–1.04) 0.057
0.474 1.61 (0.48–5.36) 0.434
0.930 2.54 (0.99–6.49) 0.053
1.055 0.35 (0.11–1.10) 0.071
0.118 0.89 (0.35–2.27) 0.802
0.318 0.73 (0.20–2.71) 0.626
0.265 1.30 (0.48–3.56) 0.599
: standards for reporting diagnostic accuracy; QUADAS: quality
ral effusion.
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Figure 3 Funnel graph for the assessment of potential
publication bias in adenosine deaminase assays. The funnel
graph plots the log of the diagnostic odds ratio (DOR) against
the standard error of the log of the DOR (an indicator of sample
size). Each solid circle represents each study in the meta-
analysis. The line in the center indicates the summary DOR.
Q.-L. Liang et al.750thoracotomy. These procedures which require expertise,
may cause complications and even increase the morbidity of
the patients.
Pleural levels of a number of biomarkers have been
proposed as aids in the diagnosis of TPE, including those of
ADA, interferon-g, interleukin-12p40, interleukin-18, immu-
nosuppressive acidic protein, and soluble interleukin-2
receptor, the levels of which are all significantly higher in
TPE than in non-TPE.111,112 Hiraki and colleagues have
compared directly the sensitivities of these markers in a
study.112 ROC analysis demonstrated that interferon-g is the
most sensitive and specific indicator of TPE among the above
six biological markers (AUC, 1.00). The next most sensitive
was soluble interleukin-2 receptor (AUC, 0.99), followed by
ADA (AUC, 0.96), interleukin-18 (AUC, 0.95), immunosup-
pressive acidic protein (AUC, 0.93), and interleukin-12p40
(AUC, 0.87). The SROC curve and its AUC present an overall
summary of test performance, and display the trade off
between sensitivity and specificity. The present meta-
analysis has shown that the mean sensitivity of ADA assay
was 0.92, while mean specificity was 0.90, and that the
maximum joint sensitivity and specificity was 0.91, while
AUC was 0.96, indicating a relative high level of overall
accuracy.
The DOR is a single indicator of test accuracy113 that
combines the data from sensitivity and specificity into a
single number. The DOR of a test is the ratio of the odds of
positive test results in the diseased relative to the odds of
positive test results in the non-diseased. The value of a DOR
ranges from 0 to infinity, with higher values indicating better
discriminatory test performance (higher accuracy). A DOR of
1.0 indicates that a test does not discriminate between
patients with the disorder and those without it. In the
present meta-analysis, we have found that the mean DOR
was 110.08, also indicating a high level of overall accuracy.
Since the SROC curve and the DOR are not easy to
interpret and use in clinical practice,114 and since likelihood
ratios are considered more clinically meaningful,114,115 we
also presented both PLR and NLR as our measures ofdiagnostic accuracy. A PLR value of 9.03 suggests that
patients with TPE have an about ninefold higher chance of
being ADA assay-positive compared with patients without
TPE. This high probability would be considered high enough
to begin or to continue anti-tuberculosis treatment of TPE,
especially in the case of the absence of any malignant
evidences. On the other hand, NLR was found to be 0.10 in
the present meta-analysis. If the ADA assay result was
negative, the probability that this patient has TPE is 10%,
which is not low enough to rule out TPE. These data suggest
that a negative ADA assay should not be used alone as a
justification to deny or to discontinue anti-tuberculosis
therapy. The choice of therapeutic strategy should be based
on the results of microscopic examination on smear or
culture for MTB and/or histological observation of pleural
tissue, as well as the other clinical data, such as response to
anti-tuberculosis therapy.
An exploration of the reasons for heterogeneity rather
than computation of a single summary measure is an
important goal of meta-analysis.116 In our meta-analysis,
both STARD and QUADAS scores were used in the metare-
gression analysis to assess the effect of study quality on
RDOR. We did not observe the studies with higher quality
(STARDX11 or QUADASX10) had a better test performance
than those with lower quality, although we found a
significant heterogeneity for sensitivity, specificity, PLR,
NLR, and DOR between these studies. We also noted that
diagnostic standard (all with gold standard versus in part
with gold standard), ADA assay method (Giusti method
versus non-Giusti methods), cut-off value (440 IU/L versus
p40 IU/L), with or without empyema or transudative
effusion included in non-TPE group did not substantially
affect diagnostic accuracy.
Our data were consistent with the results of the previous
meta-analyses on the accuracy of ADA assays by Greco and
colleagues.4,5 It should be mentioned that PLR, NLR, and
DOR have not been evaluated in those two meta-analyses. In
addition, some studies involving less than 10 TPE specimens
were also included in the both meta-analyses, while the
other studies could be included were missed. We updated
that previous meta-analysis by including more recent
related studies. An important strength of our study was its
comprehensive search strategy. Screening, study selection,
and quality assessment were done independently and
reproducibly by two reviewers. Data extraction and quality
assessment were done blinded to reduce bias. We also
explored heterogeneity and potential publication bias in
accordance with published guidelines. On the other hand,
our meta-analysis had limitations. Exclusion of conference
abstracts, letters to the editors, and non-English language
studies may have led to publication bias, which was found in
the present meta-analysis. However, a review of these
abstracts and letters suggests that the overall results
were similar to the results in the included English language
studies. Publication bias may also be introduced by
inflation of diagnostic accuracy estimates since studies that
report positive results are more likely to be accepted for
publication.
It should be emphasized that a definite diagnosis of TPE is
achieved when MTB is demonstrated in sputum or pleural
specimens, or when caseating granulomas are found in
pleural biopsy specimens. As abovementioned, microscopy
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ADA in diagnosis of TB pleurisy 751of the pleural fluid is rarely positive (o5%).107,108 Histolo-
gical examination of pleura by needle biopsy is not
conclusive in 20–40% of patients with TPE.107,108 When the
pleural biopsy is negative, mycobacteria can be cultured in
pleural specimens in less than 10% of patients,107 and this
usually takes at least three weeks. Where diagnostic
difficulty exists, several biomarkers, such as ADA and
interferon-g, in pleural fluid are useful and clinicians can
embark on empirical anti-tuberculosis therapy while await-
ing culture results, especially in young patients from areas
with a high prevalence of tuberculosis. One criticism of the
use of biomarkers rather than cultures for the diagnosis
of TPE is that culture results are not available to guide anti-
tuberculosis therapy. First and foremost among the
short comings is the fact that none of the biomarkers
including ADA provide culture and sensitivity data. Culture
results are particularly useful if drug-resistant tuberculosis
is prevalent.117
In a recent meta-analysis,118 we have reported that the
summary estimates for interferon-g in the diagnosis of TPE
were sensitivity 0.89 (95% CI 0.87–0.91), specificity 0.97
(95% CI 0.96–0.98), PLR 23.45 (95% CI 17.31–31.78), NLR
0.11 (95% CI 0.07–0.16), and DOR 272.7 (147.5–504.2).
Based on the comparison of the above measures, the overall
accuracy of interferon-g determination for the diagnosis of
TPE seemed to be somehow better than that of ADA.
In conclusion, current evidence suggests a potential role
for ADA assays in confirming a diagnosis of TPE. Since none of
pleural fluid biomarkers including ADA is specific for TPE,
the results of ADA assays should be interpreted in parallel
with clinical findings and the results of conventional tests
including microbiologic examination and pleural biopsy.Conflict of interest statement
None of the authors have a financial relationship with a
commercial entity that has an interest in the subject of this
manuscript.References
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